Chemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), post-infectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patient's quality of life, no established treatment for taste disorders exists so far. A recent report on the effect of pramipexole, a D2/D3 agonist, on taste performance in healthy subjects provides support for a new potential therapeutic target for taste dysfunction to be tested in future randomized, placebo-controlled, clinical trials across several populations reporting gustatory symptoms.
D2/D3 receptor agonism: paving the way for a new therapeutic target for taste disorders in Parkinson's disease and other conditions?
Mantovani E.;Tamburin S.
2022-01-01
Abstract
Chemosensory (i.e., olfaction and taste) dysfunction is common in neurodegenerative (e.g., Parkinson's disease, Alzheimer's disease, and dementia), psychiatric (e.g., depression, bipolar disorders, other conditions), post-infectious (i.e., long COVID) diseases and in the elderly. Despite its impact on patient's quality of life, no established treatment for taste disorders exists so far. A recent report on the effect of pramipexole, a D2/D3 agonist, on taste performance in healthy subjects provides support for a new potential therapeutic target for taste dysfunction to be tested in future randomized, placebo-controlled, clinical trials across several populations reporting gustatory symptoms.
| File | Dimensione | Formato | |
|---|---|---|---|
|
pyac042.pdf
accesso aperto
Descrizione: CC BY 4.0 publisher version
Tipologia:
Versione dell'editore
Licenza:
Creative commons
Dimensione
274.52 kB
Formato
Adobe PDF
|
274.52 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
